Lataa...
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7140029/ https://ncbi.nlm.nih.gov/pubmed/32235752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12030751 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|